MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on June 26, 2008; DOI: 10.1124/mol.108.050062

0026-895X/08/7403-541-543$20.00
Mol Pharmacol 74:541-543, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.108.050062v1
74/3/541    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kenakin, T. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kenakin, T. P.
Perspective

Seven Transmembrane Receptors as Nature's Prototype Allosteric Protein: De-emphasizing the Geography of Binding

Terry P. Kenakin

GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina

The article in this issue by Redka et al. (p. 834) illustrates some interesting interactions between classified orthosteric (bind to the same recognition site as endogenous agonist) and allosteric (bind to a different site) ligands. Of particular interest are the methods used to deal with an obfuscating factor in these kinds of studies, namely the propensity of seven transmembrane receptors to form dimers and thus demonstrate allosteric effects through binding at the orthosteric site. The judicious use of kinetics to detect and quantify allosteric action also is demonstrated. The various unique properties of allosteric modulators are discussed in the context of the increasing prevalence of allosteric ligands as investigational drugs.

Received June 25, 2008; accepted June 26, 2008

Address correspondence to: Dr. Terry Kenakin, Department of Biological Reagents and Assay Development, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709. E-mail: terry.p.kenakin{at}gsk.com


Related articles in MolPharm:

Binding of Orthosteric Ligands to the Allosteric Site of the M2 Muscarinic Cholinergic Receptor
Dar'ya S. Redka, Luca F. Pisterzi, and James W. Wells
MolPharm 2008 74: 834-843. [Abstract] [Full Text]  





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics